Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

ClinicalTrials.gov ID: NCT03100344

Public ClinicalTrials.gov record NCT03100344. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving Topical Corticosteroids (TCS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.

Study identification

NCT ID
NCT03100344
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Galderma R&D
Industry
Enrollment
226 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 13, 2017
Primary completion
Jul 18, 2018
Completion
Sep 20, 2018
Last update posted
Oct 21, 2019

2017 – 2018

United States locations

U.S. sites
26
U.S. states
14
U.S. cities
24
Facility City State ZIP Site status
Galderma Investigational site Birmingham Alabama 35209
Galderma Investigational site Fort Smith Arkansas 72916
Galderma Investigational site Beverly Hills California 90212
Galderma Investigational site Fountain Valley California 92708
Galderma Investigational site Fremont California 94538
Galderma Investigational site Rolling Hills Estates California 90274
Galderma Investigational site Santa Ana California 92701
Galderma Investigational site Santa Monica California 90404
Galderma Investigational site Miami Florida 33135
Galderma Investigational site Tampa Florida 33607
Galderma Investigational Site Tampa Florida 33624
Galderma Investigational site Columbus Georgia 31904
Galderma Investigational site Sandy Springs Georgia 30328
Galderma Investigational Site Darien Illinois 60561
Galderma Investigational Site Overland Park Kansas 66215
Galderma Investigational site New Orleans Louisiana 70115
Galderma Investigational Site Farmington Hills Michigan 78334
Galderma Investigational site Forest Hills New York 11375
Galderma Investigational site New York New York 10025
Galderma Investigational Site New York New York 10075
Galderma Investigational site Chapel Hill North Carolina 27516
Galderma Investigational Site Johnston Rhode Island 02919
Galderma Investigational site Dallas Texas 75230
Galderma Investigational site San Antonio Texas 78218
Galderma Investigational Site Waco Texas 76710
Galderma Investigational site Richmond Virginia 23220

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03100344, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 21, 2019 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03100344 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →